

CITATION REPORT

List of articles citing

Benign prostatic hyperplasia

DOI: 10.1016/s0140-6736(03)13073-5
Lancet, The, 2003, 361, 1359-67.

Source: <https://exaly.com/paper-pdf/35485395/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
239	Clinical relevance of bleeding index. 2003 , 163, 2794; author reply 2794-5		2
238	Emerging pharmacologic approaches for the treatment of lower urinary tract disorders. 2004 , 308, 797-804		24
237	Molecular profiling of benign prostatic hyperplasia using a large scale real-time reverse transcriptase-polymerase chain reaction approach. <i>Journal of Urology</i> , 2004 , 172, 1382-5	2.5	11
236	Significado clínic de un PSA elevado. 2004 , 11, 604-613		
235	Alcohol and the risk of prostate cancer and benign prostatic hyperplasia. 2004 , 64, 717-22		37
234	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. 2005 , 15, 657-64		31
233	Pharmacophore-based design, synthesis, biological evaluation, and 3D-QSAR studies of aryl-piperazines as alpha(1)-adrenoceptor antagonists. 2005 , 15, 3216-9		26
232	Noninvasive management of lower urinary tract symptoms and sexual dysfunction associated with benign prostatic hyperplasia in the primary care setting. 2005 , 31, 194-208		2
231	Association of cigarette smoking, alcohol consumption and physical activity with lower urinary tract symptoms in older American men: findings from the third National Health And Nutrition Examination Survey. 2005 , 96, 77-82		99
230	Selecting therapy for maintaining sexual function in patients with benign prostatic hyperplasia. 2005 , 96, 237-43		5
229	Low incidence of acute urinary retention in the general male population: the triumph project. 2005 , 47, 494-8		45
228	Gender differences in drug use and expenditures in a privately insured population of older adults. 2005 , 14, 73-81		21
227	Limitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the community. 2005 , 80, 759-64		15
226	The Impact of Nocturia on Health Status and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH). 2005 , 4, 1-8		6
225	Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia. 2005 , 3, 103-14		19
224	Limitations of Using Outcomes in the Placebo Arm of a Clinical Trial of Benign Prostatic Hyperplasia to Quantify Those in the Community. 2005 , 80, 759-764		11
223	Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4-chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clophenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subtypes in the regulation of human PC-3 prostate cancer cell apoptosis and proliferation. 2005 , 49, 7750-63		22

222	[Management of patients with benign prostatic hyperplasia by urologists: the DUO study]. 2006 , 40 Suppl 3, S58-63		
221	Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience. <i>Journal of Urology</i> , 2006 , 175, 35-42	2.5	12
220	Clinical approach to the prostate: an update. 2006 , 44, 649-63, vii		4
219	Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol). 2006 , 29, 665-74		21
218	In vitro effect of D-004, a lipid extract of the fruit of the cuban royal palm (<i>Roystonea regia</i>), on prostate steroid 5 β -reductase activity. 2006 , 67, 396-405		14
217	Plasma levels, tissue distribution, and excretion of radioactivity after single-dose administration of ((3)H)-oleic acid added to D-004, a lipid extract of the fruit of <i>Roystonea regia</i> , in rats. 2006 , 67, 406-19		7
216	The flavonoid apigenin inhibits the proliferation of prostatic stromal cells via the MAPK-pathway and cell-cycle arrest in G1/S. 2006 , 55, S37-S46		20
215	Benign Prostatic Hyperplasia. 2006 , 641-649		
214	Dioxin exposure and benign prostatic hyperplasia. 2006 , 48, 708-14		9
213	Quantification of alpha1-adrenoceptor subtypes by real-time RT-PCR and correlation with age and prostate volume in benign prostatic hyperplasia patients. 2006 , 66, 761-7		41
212	Mepartricin long-term administration regulates steroid hormone and adrenergic receptor concentrations in the prostate of aged rats. 2006 , 29, 289-97		4
211	The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. 2006 , 50, 440-52; discussion 453		100
210	Lifetime occupational and recreational physical activity and risk of benign prostatic hyperplasia. 2006 , 118, 2632-5		35
209	Use of finasteride plus doxazosin combination therapy for treatment of LUTS related to benign prostatic hyperplasia. 2007 , 3, 437-443		
208	Benign Prostatic Hyperplasia. 2007 ,		
207	Effect of Physical Activity on Women at Increased Risk of Breast Cancer: Results from the E3N Cohort Study. <i>Yearbook of Sports Medicine</i> , 2007 , 2007, 201-203		
206	[Factors determining treatment strategies for patients with benign prostatic hyperplasia. The DUO study]. 2007 , 36, 755-63		4
205	[Importance of nocturia and its impact on quality of sleep and quality of life in patient with benign prostatic hyperplasia]. 2007 , 31, 262-9		11

204	Pharmacophore-guided design, synthesis and evaluation of quinazoline-arylpiperazines as new α -adrenoceptor antagonists. 2007 , 18, 41-44	5
203	Association of IGF-1 and IGFBP-3 with lower urinary tract symptoms in the third national health and nutrition examination survey. 2007 , 67, 1693-8	19
202	Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. 2008 , 6, 24-30	
201	5- α -reductase inhibitor monotherapy for lower urinary tract symptoms following combination therapy with α -blockers: When is one medication enough?. 2008 , 6, 74-78	1
200	Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. 2008 , 9, 295-301	1
199	Water intake and bladder cancer risk in Los Angeles County. 2008 , 123, 1649-56	36
198	Design, synthesis and biological estimation of 1-(benzoxazole-2-yl)piperazine and 4-(benzoxazole-2-yl)piperidine derivatives as potential α -AR antagonists. 2008 , 19, 1193-1195	6
197	Male genital tract pharmacology: developments in quantitative methods to better understand a complex peripheral compartment. 2008 , 83, 401-12	12
196	Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. 2008 , 102, 1400-6	26
195	Drug-induced urinary retention: incidence, management and prevention. 2008 , 31, 373-88	137
194	Effects of D-004, a lipid extract of the fruit of the Cuban royal palm (<i>Roystonea regia</i>) or the lipidosterolic extract of saw palmetto (<i>Serenoa repens</i>) on the sexual activity in male rats: A controlled, experimental study. 2008 , 69, 65-74	2
193	Effect of CKBM on prostate cancer cell growth in vitro and in vivo. 2008 , 20, 246-52	1
192	Oral subchronic toxicity of a lipid extract from <i>Roystonea regia</i> fruits in mice. 2008 , 31, 217-28	7
191	Noninvasive quantitation of drug concentration in prostate and seminal vesicles: improvement and validation with desipramine and aspirin. 2008 , 48, 176-83	3
190	17Beta-estradiol at low concentrations acts through distinct pathways in normal versus benign prostatic hyperplasia-derived prostate stromal cells. 2009 , 150, 4594-605	14
189	Silodosin: a selective α 1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia. 2009 , 31, 2489-502	52
188	Benign prostatic hyperplasia: evaluation of T1, T2, and microvascular characteristics with T1-weighted dynamic contrast-enhanced MRI. 2009 , 29, 641-8	47
187	Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction. 2010 , 106, 287-93	20

186	Polyphenol composition and antioxidant capacity of Epilobium species. 2009 , 49, 26-31	64
185	Scrotal herniation of the ureter: a rare late complication after renal transplantation. 2009 , 41, 1393-7	7
184	Efficacy of combined amlodipine/terazosin therapy in male hypertensive patients with lower urinary tract symptoms: a randomized, double-blind clinical trial. 2009 , 74, 130-6	8
183	cGMP: Generators, Effectors and Therapeutic Implications. 2009 ,	13
182	Ejaculatory duct obstruction after transurethral resection of the prostate. 2009 , 109, 818-9	1
181	Effects of coconut oil on testosterone-induced prostatic hyperplasia in Sprague-Dawley rats. 2007 , 59, 995-9	21
180	The different reduction rate of prostate-specific antigen in dutasteride and finasteride. 2010 , 51, 704-8	12
179	Silodosin in the treatment of benign prostatic hyperplasia. 2010 , 4, 291-7	22
178	Analysis of the factors causing bladder irritation after transurethral resection of the prostate. 2010 , 51, 700-3	6
177	[Diagnostic and therapeutic management of the benign prostatic hyperplasia by the general practitioners in the Maine-et-Loire]. 2010 , 20, 65-70	0
176	Adipose derived stem cells ameliorate hyperlipidemia associated detrusor overactivity in a rat model. <i>Journal of Urology</i> , 2010 , 183, 1232-40	2.5 81
175	Influence of detrusor overactivity on storage symptoms following potassium-titanyl-phosphate photoselective vaporization of the prostate. 2010 , 75, 1460-6	14
174	Modified vaporization-resection for photoselective vaporization of the prostate using a GreenLight high-performance system 120-W Laser: the Seoul technique. 2011 , 77, 427-32	28
173	Antiproliferative and cytotoxic activity of extracts from <i>Cistus incanus</i> L. and <i>Cistus monspeliensis</i> L. on human prostate cell lines. 2011 , 25, 188-202	13
172	Early Efficacy of an α Adrenoceptor Antagonist, Naftopidil, against Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2011 , 3, 79-85	1.9 2
171	Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia. 2011 , 6, 161-72	23
170	Treating benign prostatic hyperplasia with botulinum neurotoxin. 2011 , 18, 3468-75	1
169	Silodosin: pharmacological and clinical features. 2011 , 7, 45-57	2

168	Risk of prostate cancer associated with benign prostate disease: a primary care case-control study. 2011 , 61, e684-91		5
167	Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). 2011 , 163, 891-907		51
166	Effects of in utero exposure to D-004, a lipid extract from <i>Roystonea regia</i> fruits, in the male rat: a comparison with finasteride. 2011 , 14, 1663-9		3
165	Vitamin D Receptor Agonists in the Treatment of Benign Prostatic Hyperplasia. 2011 , 1931-1941		
164	Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia. 2012 , 4, 267-72		4
163	Combination treatment with tamsulosin and dutasteride for benign prostatic hyperplasia. 2012 , 8, 555-565		
162	Automatic differential segmentation of the prostate in 3-D MRI using Random Forest classification and graph-cuts optimization. 2012 ,		10
161	Effect of Discontinuation of Tamsulosin in Korean Men with Benign Prostatic Hyperplasia Taking Tamsulosin and Dutasteride: An Open-Label, Prospective, Randomized Pilot Study. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2012 , 4, 35-40	1.9	7
160	Silodosin (Urief [®] , Rapaflo [®] , Thrupas [®] , Urorec [®] , Silodix [®]) A Selective α_1 Adrenoceptor Antagonist for the Treatment of Benign Prostatic Hyperplasia. 2012 , 360-391		
159	Alcohol consumption shows a J-shaped association with lower urinary tract symptoms in the general screening population. <i>Journal of Urology</i> , 2012 , 187, 1312-7	2.5	9
158	[Initial assessment and follow-up of benign prostatic hyperplasia: systematic review of the literature by the LUTS committee of the French Urological Association]. 2012 , 22, 1-6		2
157	Baus Medical Student Essay Competition: Medical Management of Symptomatic Benign Prostatic Enlargement. 2012 , 5, 297-301		
156	Patented prostate cancer biomarkers. 2012 , 9, 464-72		10
155	Recurrent Urinary Tract Infections in Men. 2012 , 39-53		
154	Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia. 2012 , 13, 2085-96		23
153	Benign Prostate Hyperplasia and Chronic Kidney Disease. 2012 ,		0
152	Kidney and genitourinary tract. 2012 , 452-466		
151	Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel- and lectin-based proteomics analyses. 2012 , 33, 1855-62		29

150	Local inflammation influences oestrogen metabolism in prostatic tissue. 2012 , 110, 274-82	15
149	Effect of silodosin on detrusor overactivity in the male spontaneously hypertensive rat. 2012 , 110, E118-24	29
148	The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of ≤ 0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial. 2012 , 110, 638-43	11
147	Homologous recombination induced by doxazosin mesylate and saw palmetto in the <i>Drosophila</i> wing-spot test. 2013 , 33, 209-13	2
146	Folate and B12 in prostate cancer. 2013 , 60, 1-63	14
145	A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. 2013 , 21, 172-9	31
144	Lower urinary tract symptoms in relation to region of birth in 95,393 men living in Australia: the 45 and Up Study. 2013 , 31, 673-82	12
143	Relationship between endothelial dysfunction and nocturia with benign prostatic hyperplasia. 2013 , 47, 384-9	10
142	[Benign prostatic hyperplasia and its treatment: impact on quality of life and sexual function]. 2013 , 37, 233-41	3
141	Protective effect of 2-hydroxy-4-methoxy benzoic acid on testosterone induced benign prostatic hyperplasia in Wister rats. 2013 , 698, 397-403	18
140	Current pharmacological treatment options for male lower urinary tract symptoms. 2013 , 14, 1043-54	4
139	Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia. 2013 , 33, 639-49	16
138	Experience of transurethral resection of the prostate: a qualitative study. 2013 , 7, 68-75	2
137	Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5 α -reductase inhibitors. 2013 , 81, 979-84	19
136	Anthocyanins extract from bilberry enhances the therapeutic effect of pollen of <i>Brassica napus</i> L. on stress-provoked benign prostatic hyperplasia in restrained mice. 2013 , 5, 1357-1365	18
135	Benign prostatic hyperplasia and its treatment: Impact on quality of life and sexual function. 2013 , 37, 233-241	3
134	Urinary retention: benefit of gradual bladder decompression - myth or truth? A randomized controlled trial. 2013 , 91, 140-4	13
133	Enablers and barriers affecting medication-taking behaviour in aging men with benign prostatic hyperplasia. 2013 , 16, 112-7	2

132	Prostatic arterial embolization for benign prostatic hyperplasia: short- and intermediate-term results. 2013 , 266, 668-77		110
131	[5ARI and PSA: evidences]. 2014 , 81 Suppl 24, 4-11		1
130	Tolterodine to relieve urinary symptoms following transurethral resection of the prostate: a double-blind placebo-controlled randomized clinical trial. 2014 , 55, 260-4		9
129	Predictors of short-term overactive bladder symptom improvement after transurethral resection of prostate in men with benign prostatic obstruction. 2014 , 21, 1035-40		18
128	Efficacy and Safety of the Selective α -Adrenoceptor Blocker Silodosin for Severe Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Prospective, Single-Open-Label, Multicenter Study in Korea. 2014 , 55, 335-40		1
127	Abdomen and Thoracic Imaging. 2014 ,		3
126	Long-term use of 5 α -reductase inhibitors and the risk of male breast cancer. 2014 , 25, 1577-82		24
125	MRI findings after prostatic artery embolization for treatment of benign hyperplasia. 2014 , 203, 813-21		56
124	[Evolution of lower urinary tract symptoms under silodosin: factors influencing patientsQ satisfaction]. 2014 , 24, 196-202		1
123	Inhibitory effect of rape pollen supercritical CO fluid extract against testosterone-induced benign prostatic hyperplasia in rats. 2014 , 8, 31-37		3
122	Identification and validation of potential new biomarkers for prostate cancer diagnosis and prognosis using 2D-DIGE and MS. 2015 , 2015, 454256		35
121	Expression of Heat Shock Protein 27 in Benign Prostatic Hyperplasia with Chronic Inflammation. 2015 , 21, 2976-85		7
120	Seasonal Variation of Urinary Symptoms in Korean Men with Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia. <i>World Journal of Men's Health</i> , 2015 , 33, 81-7	6.8	13
119	EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. 2015 , 67, 1099-1109		541
118	Discovery of novel 5 α -reductase type II inhibitors by pharmacophore modelling, virtual screening, molecular docking and molecular dynamics simulations. 2015 , 41, 287-297		2
117	A novel robotic platform for laser-assisted transurethral surgery of the prostate. 2015 , 62, 489-500		26
116	Preventive effect of Pueraria mirifica on testosterone-induced prostatic hyperplasia in Sprague Dawley rats. 2015 , 47, 1153-9		9
115	Inhibitory effects of Tripterygium wilfordii multiglycoside on benign prostatic hyperplasia in rats. 2015 , 13, 421-7		6

114	Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH. 2015 , 33, 697-706	9
113	The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia by primary care family physicians in Portugal. 2015 , 35 Suppl 1, 19-27	1
112	The impact of the bladder wall thickness on the outcome of the medical treatment using alpha-blocker of BPH patients with LUTS. 2015 , 18, 89-92	12
111	Serum Electrolyte Disturbances in Benign Prostate Hyperplasia after Transurethral Resection of the Prostate. 2016 , 06,	
110	Efficacy of β -blocker in improving ureteral stent-related symptoms: a meta-analysis of both direct and indirect comparison. 2016 , 10, 1783-93	7
109	Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: a large, cross-sectional, UK epidemiological study. 2016 , 117, 801-8	21
108	Design, Synthesis, and Biological Evaluation of Indoline and Indole Derivatives as Potent and Selective α -Adrenoceptor Antagonists. 2016 , 59, 3826-39	17
107	In vivo metabolic investigation of silodosin using UHPLC-QTOF-MS/MS and in silico toxicological screening of its metabolites. 2016 , 51, 867-882	2
106	Management of Benign Prostatic Hyperplasia in Older Adults. 2016 , 31, 412-24	15
105	Efectos secundarios de los inhibidores de 5 α -reductasa en el tratamiento de hiperplasia prostática benigna. 2016 , 76, 265-266	
104	Detection of benign prostatic hyperplasia nodules in T2W MR images using fuzzy decision forest. 2016 ,	
103	Design, Synthesis, and Biological Evaluation of Novel Tetrahydroprotoberberine Derivatives (THPBs) as Selective α -Adrenoceptor Antagonists. 2016 , 59, 9489-9502	17
102	Prevalence and Progression of Lower Urinary Tract Symptoms in an Aging Population. 2016 , 95, 158-63	22
101	Benign prostatic hyperplasia: Case report of a 17-year-old. 2016 , 12, 267.e1-4	3
100	Uvaria rufa Blume attenuates benign prostatic hyperplasia via inhibiting 5 α -reductase and enhancing antioxidant status. 2016 , 194, 483-494	10
99	Prostatic Artery Embolization: A Promising Technique in the Treatment of High-Risk Patients with Benign Prostatic Hyperplasia. 2016 , 97, 320-324	12
98	Surgical Management of Male Voiding Dysfunction. 2016 , 96, 491-501	4
97	A case of giant prostatic hyperplasia. 2016 , 3, 53-55	7

96	Incidence of complications in men undergoing transurethral resection of the prostate. 2017 , 24, 3-9	5
95	Characterization of degradation products of silodosin under stress conditions by liquid chromatography/Fourier transform mass spectrometry. 2017 , 31, 572-582	4
94	Predictors of Improvement in Storage Symptoms at Three Years After 120W GreenLight High Performance System Laser Treatment for Benign Prostate Hyperplasia. 2017 , 31, 666-673	2
93	Association between human papillomavirus and prostate cancer: A meta-analysis. 2017 , 14, 1855-1865	14
92	Polypharmacy, chronic kidney disease, and benign prostatic hyperplasia in patients with chronic obstructive pulmonary disease newly treated with long-acting anticholinergics. 2017 , 132, 195-202	2
91	Association between chronic obstructive pulmonary disease and increased risk of benign prostatic hyperplasia: a retrospective nationwide cohort study. <i>BMJ Open</i> , 2017 , 7, e015581	3 4
90	LC-ESI-MS/MS evaluation of forced degradation behaviour of silodosin: In vitro anti cancer activity evaluation of silodosin and major degradation products. 2017 , 134, 1-10	9
89	Bawu decoction () ameliorates benign prostatic hyperplasia in rats. 2017 , 23, 611-616	1
88	Preventive Effects of Resveratrol-enriched Extract of Peanut Sprout on Bacteria- and Estradiol-induced Prostatitis in Mice. 2017 , 12, 1934578X1701200	2
87	Clinical evaluation of embolization of the superior vesical prostatic artery for treatment of benign prostatic hyperplasia: a single-center retrospective study. 2017 , 12, 409-416	7
86	Potential repositioning of GV1001 as a therapeutic agent for testosterone-induced benign prostatic hyperplasia. 2018 , 42, 2260-2268	3
85	Past and Present of Imaging Modalities Used for Prostate Cancer Diagnosis: Androgen Receptor Targeted Imaging of Prostate Cancer as a Future Modality for Early, Rapid and Efficient Diagnosis. 2018 , 14, 874-886	
84	Prescription pattern of alpha-blockers for management of lower urinary tract symptoms/benign prostatic hyperplasia. 2018 , 8, 13223	6
83	Diagnostic Work-up of LUTS/BPH: From Standard to New Perspectives. 2018 , 113-133	
82	Lower Urinary Tract Symptoms Following Transurethral Resection of Prostate. 2018 , 19, 85	11
81	Association between the symptoms of benign prostatic hyperplasia and social disparities: Does social capital promote prostate health?. 2018 , 50, e13125	3
80	Risk of incident benign prostatic hyperplasia in patients with gout: a retrospective cohort study. 2018 , 21, 277-286	6
79	Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms. 2018 , 13, e0191469	19

78	Prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-analysis. 2019 , 29, 287-298		66
77	Age, height, BMI and FBG predict prostate volume in ageing benign prostatic hyperplasia: Evidence from 5285 patients. 2019 , 73, e13438		4
76	The value of as a novel biomarker in the diagnosis of prostate cancer. 2019 , 47, 2241-2245		4
75	Prostate Artery Embolization for Lower Urinary Tract Symptoms in Men Unfit for Surgery. 2019 , 9,		7
74	Association of CCL2, CCR2 and CCL5 genetic polymorphisms with the development and progression of benign prostatic hyperplasia. 2019 , 41, 2491-2501		4
73	Prostate Benign Prostatic Hyperplasia. 2019 , 531-561		0
72	Visceral-afferent signals from the cardiovascular system, but not urinary urge, affect startle eye blink. 2019 , 199, 165-172		8
71	Role of poor urethral sphincter relaxation in men with voiding dysfunction refractory to α -blocker therapy: Clinical characteristics and predictive factors. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019 , 11, 8-13	1.9	2
70	Intractable hematuria due to giant prostatic hyperplasia effectively treated with prostatic artery embolization. 2020 , 7, 318-321		
69	Regulation of PDE5 expression in normal prostate, benign prostatic hyperplasia, and adenocarcinoma. 2020 , 8, 427-433		2
68	Prospective validation of a novel visual analogue uroflowmetry score (VAUS) in 1000 men with lower urinary tract symptoms (LUTS). 2020 , 38, 1267-1273		2
67	Association between asthma and risk of benign prostatic hyperplasia: a retrospective population-based study. 2020 , 23, 599-606		2
66	An updated meta-analysis of prostatic arterial embolization versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia. 2020 , 38, 2455-2468		8
65	Tight junction protein claudin-1 is downregulated by TGF- β via MEK signaling in benign prostatic epithelial cells. 2020 , 80, 1203-1215		6
64	The association between anogenital distance and benign prostatic hyperplasia related lower urinary tract symptoms in Chinese aging men. 2021 , 39, 2645-2653		0
63	Postembolization Syndrome after Prostatic Artery Embolization: A Systematic Review. 2020 , 10,		7
62	The Clinical Implication of Incidental Prostatic Amyloidosis. 2020 , 145, 253-257		3
61	The Effects of Extract on Testosterone-Induced Benign Prostatic Hyperplasia in Rats, and Quantitative Analysis of Major Constituents Depending on Extract Conditions. 2020 , 12,		2

60	Multivariate Analysis of the Failure of Removal of the Urinary Catheter within 48 Hours after Transurethral Enucleation and Resection of the Prostate. 2020 , 2020, 8241637	
59	Effect of superselective prostatic artery embolization on benign prostatic hyperplasia. 2021 , 46, 1726-1736	2
58	Imaging in Bladder Dysfunctions. 2021 , 159-183	
57	Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review. 2021 , 13, 17562872211046794	
56	PSA density in the diagnosis of prostate cancer in the Chinese population: results from the Chinese Prostate Cancer Consortium. 2021 , 23, 300-305	0
55	A call for HoLEP: en-bloc vs. two-lobe vs. three-lobe. 2021 , 39, 2337-2345	7
54	Surgical management of benign prostate hyperplasia in Nigeria: open prostatectomy versus transurethral resection of the prostate. 2021 , 39, 165	0
53	Steroidal 5 α -Reductase: A Therapeutic Target for Prostate Disorders.	0
52	Self-Management for Men With Lower Urinary Tract Symptoms: A Systematic Review and Meta-Analysis. 2021 , 19, 157-167	3
51	Evaluation of Juniperus communis L. seed extract on benign prostatic hyperplasia induced in male Wistar rats. 2021 , 27,	2
50	Feasibility, safety, and efficacy of ultrasound-guided transperineal laser ablation for the treatment of benign prostatic hyperplasia: a single institutional experience. 2021 , 39, 3867-3873	6
49	Intestinal smooth muscle aberrations in pancreatic cancer patients with sarcopenia. 2021 , 4, 187-196	0
48	Global, Regional, and National Incidence and Year Lived with Disability for Benign Prostatic Hyperplasia from 1990 to 2019. 2021 , 15, 15579883211036786	5
47	The miR-223-3p/MAP1B axis aggravates TGF- β -induced proliferation and migration of BPH-1 cells. 2021 , 84, 110004	1
46	Utilization of a micellar matrix for simultaneous spectrofluorimetric estimation of alfuzosin hydrochloride and vardenafil hydrochloride. 2022 , 266, 120420	0
45	Erectile dysfunction and lower urinary tract. 2009 , 507-31	12
44	Neue Arzneimittel 2010. 2011 , 43-117	2
43	Inhibition of Benign Prostatic Hyperplasia by Vitamin D Receptor Ligands. 2005 , 1833-1843	1

42	Correlations of Metabolic Components with Prostate Volume in Middle-Aged Men Receiving Health Check-Up. 2016 , 11, e0145050		2
41	Pharmacological properties of fireweed (<i>Epilobium angustifolium</i> L.) and bioavailability of ellagitannins. A review. 2020 , 66, 52-64		9
40	Eight Days of Water-Only Fasting Promotes Favorable Changes in the Functioning of the Urogenital System of Middle-Aged Healthy Men. 2020 , 13,		1
39	Benign prostatic hyperplasia: An overview of existing treatment. <i>Indian Journal of Pharmacology</i> , 2011 , 43, 6-12	2.5	29
38	Comparison of 80 W versus 120 W 532 nm Laser Prostatectomy for BPH. <i>Open Journal of Urology</i> , 2013 , 03, 1-4	0.2	1
37	Evaluation of Clinical Outcomes of Prostatic Urethral Lift for Benign Prostatic Hyperplasia: An Asian Population Study. <i>World Journal of Men's Health</i> , 2020 , 38, 338-344	6.8	8
36	The Design and Rationale of a Multicentre Randomised Controlled Trial Comparing Transperineal Percutaneous Laser Ablation With Transurethral Resection of the Prostate for Treating Benign Prostatic Hyperplasia. <i>Frontiers in Surgery</i> , 2021 , 8, 755957	2.3	2
35	Alfuzosin for Symptomatic Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 2006 , 175, 35??42	2.5	
34	The Changing Pattern of Serum Prostate Specific Antigen in Patients with Benign Prostatic Hyperplasia after Combined Treatment with Finasteride and α -blockers: the 3 Year Follow-up Data. <i>Korean Journal of Urology</i> , 2006 , 47, 372		3
33	Lifetime occupational and recreational physical activity and risk of benign prostatic hyperplasia. <i>Yearbook of Sports Medicine</i> , 2007 , 2007, 199-201		
32	Kidney and genitourinary tract. 2008 , 478-494		
31	Urinary Tract Disorders. 2012 , 899-927		
30	Ectopic Scrotum: A Rare Clinical Entity. <i>UroToday International Journal</i> , 2012 , 05,		
29	Nocturia: Impact on quality of life in an Egyptian adult population. <i>Advances in Aging Research</i> , 2013 , 02, 160-165	0.5	
28	Benign Prostatic Hyperplasia Mimicking a Symptomatic Rectal Submucosal Tumor. <i>Soonchunhyang Medical Science</i> , 2015 , 21, 164-168	0.2	
27	Efficacy of dexamethasone in reducing the postembolisation syndrome in men undergoing prostatic artery embolisation for benign prostatic hyperplasia: protocol for a single-centre, randomised, double-blind, placebo-controlled trial-the QEXAPAEQstudy. <i>BMJ Open</i> , 2021 , 11, e047878	3	
26	Can new, improvised Visual Prostate Symptom Score replace the International Prostate Symptom Score? Indian perspective. <i>Indian Journal of Urology</i> , 2020 , 36, 123-129	0.8	2
25	Peritoneum and Pelvis. 2021 , 273-289		

24	COVID-19: systemic pathology and its implications for therapy.. <i>International Journal of Biological Sciences</i> , 2022 , 18, 386-408	11.2	5
23	Nutritional and surgical aspects in prostate disorders.. <i>Critical Reviews in Food Science and Nutrition</i> , 2022 , 1-17	11.5	
22	Influence of Prostate Artery Embolization on Different Qualities of Lower Urinary Tract Symptoms Due to Benign Prostatic Obstruction.. <i>European Urology Focus</i> , 2022 ,	5.1	0
21	iVoiding: A Thermal-Image based Artificial Intelligence Dynamic Voiding Detection System. 2022 ,		
20	Risk factors for pharmacotherapy for storage symptoms after transurethral resection of the prostate in patients with benign prostatic hyperplasia.. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2022 ,	1.9	
19	Prostatic artery embolization in men with severe hemophilia a: a case report of two patients.. <i>CVIR Endovascular</i> , 2022 , 5, 21	1.5	
18	A case report of giant prostatic hyperplasia in a resource-challenged center.. <i>Urology Case Reports</i> , 2022 , 43, 102094	0.5	
17	The Prostate-Associated Gene 4 (PAGE4) Could Play a Role in the Development of Benign Prostatic Hyperplasia under Oxidative Stress. <i>Oxidative Medicine and Cellular Longevity</i> , 2022 , 2022, 1-22	6.7	
16	Administration of Caesalpinia bonduc Seed Extracts Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia (BPH) in Male Wistar Rats. <i>Research and Reports in Urology</i> , Volume 14, 225-239	1.3	0
15	Vorastins A: Pyridinium Alkaloids from the Marine Dinoflagellate <i>Effrenium voratum</i> with Inhibitory Effects on Biomarkers for Benign Prostatic Hyperplasia. <i>Journal of Natural Products</i> , 2022 , 85, 1495-1502	4.9	
14	A synchronous spectrofluorometric technique for simultaneous detection of alfuzosin and tadalafil: applied to tablets and spiked biological samples. <i>Royal Society Open Science</i> , 2022 , 9,	3.3	0
13	Comparison of Tamsulosin and Tadalafil effects in LUTS treatment considering patientsQ atherosclerosis risk level. <i>Annals of Medicine and Surgery</i> , 2022 , 80, 104137	2	
12	Impact of COVID-19 on male urogenital health: Success of vaccines. 2022 , 103327		
11	Silencing of LLGL2 Suppresses the Estradiol-Induced BPH-1 Cell Proliferation through the Regulation of Autophagy. 2022 , 10, 1981		
10	Acute urinary retention in men: 21-year trends in incidence, subsequent benign prostatic hyperplasia-related treatment and mortality: A Danish population-based cohort study.		0
9	Sargassum horneri Extract Alleviates Testosterone-Induced Benign Prostatic Hyperplasia In Vitro and In Vivo. 1-12		0
8	Quality by design-guided development of a capillary electrophoresis method for the chiral purity determination of silodosin. 2023 , 222, 115117		0
7	Decoding ceRNA regulatory network and autophagy-related genes in benign prostatic hyperplasia. 2022 ,		0

- 6 Applications of Microwaves in Medicine. **2022**, 1-36 1
- 5 Panax ginseng C.A. meyer alleviates benign prostatic hyperplasia while preventing finasteride-induced side effects. 14, 0
- 4 Mendelian Randomization Study of Causality between Benign Prostatic Hyperplasia and Erectile Dysfunction. **2023**, 13, 1356-1363 0
- 3 Evaluating the effectiveness of tranexamic acid administration in reducing bleeding in benign prostate hyperplasia patients underwent open prostatectomy: A double-blind randomized clinical trial. **2023**, 28, 8 0
- 2 Long-term risk of benign prostatic hyperplasia-related surgery and acute urinary retention in men treated with 5-alpha reductase inhibitor versus alpha-blocker monotherapy in routine clinical care. 0
- 1 Research Progress of Benign Prostatic Hy-perplasia and Lower Urinary Tract Symp-toms. **2023**, 13, 5914-5919 0